Vertex Pharmaceuticals, Inc. (VRTX)
547.74
-0.31
(-0.06%)
USD |
NASDAQ |
Aug 24, 16:00
548.20
+0.46
(+0.08%)
After-Hours: 20:00
Vertex Pharmaceuticals Profit Margin (Quarterly) : 32.89% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 32.89% |
| March 31, 2026 | 34.24% |
| December 31, 2025 | 36.91% |
| September 30, 2025 | 34.76% |
| June 30, 2025 | 34.59% |
| March 31, 2025 | 23.54% |
| December 31, 2024 | 31.62% |
| September 30, 2024 | 37.67% |
| June 30, 2024 | -136.4% |
| March 31, 2024 | 40.92% |
| December 31, 2023 | 38.44% |
| September 30, 2023 | 41.73% |
| June 30, 2023 | 36.85% |
| March 31, 2023 | 29.74% |
| December 31, 2022 | 36.39% |
| September 30, 2022 | 41.01% |
| June 30, 2022 | 37.68% |
| March 31, 2022 | 36.69% |
| December 31, 2021 | 37.32% |
| September 30, 2021 | 42.82% |
| June 30, 2021 | 3.70% |
| March 31, 2021 | 37.52% |
| December 31, 2020 | 36.85% |
| September 30, 2020 | 43.19% |
| June 30, 2020 | 55.15% |
| Date | Value |
|---|---|
| March 31, 2020 | 40.02% |
| December 31, 2019 | 41.48% |
| September 30, 2019 | 6.12% |
| June 30, 2019 | 28.66% |
| March 31, 2019 | 31.54% |
| December 31, 2018 | |
| September 30, 2018 | 16.41% |
| June 30, 2018 | 27.32% |
| March 31, 2018 | 35.46% |
| December 31, 2017 | 15.67% |
| September 30, 2017 | -50.38% |
| June 30, 2017 | 5.74% |
| March 31, 2017 | 34.86% |
| December 31, 2016 | 6.05% |
| September 30, 2016 | -9.56% |
| June 30, 2016 | -8.38% |
| March 31, 2016 | -9.07% |
| December 31, 2015 | -18.29% |
| September 30, 2015 | -30.28% |
| June 30, 2015 | -133.1% |
| March 31, 2015 | -143.5% |
| December 31, 2014 | -125.0% |
| September 30, 2014 | -94.98% |
| June 30, 2014 | -115.1% |
| March 31, 2014 | -196.2% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -134.2% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Regeneron Pharmaceuticals, Inc. | 30.23% |
| Sionna Therapeutics, Inc. | -- |
| Biogen, Inc. | 3.72% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 23.74% |
| Return on Assets | 17.08% |
| Return on Invested Capital | 21.57% |
| Gross Profit Margin (Quarterly) | 85.37% |
| Operating Margin (Quarterly) | 38.24% |
| Return on Net Operating Assets | 53.20% |